DARUNAVIR SANDOZ darunavir 600 mg tablet bottle

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

darunavir, Quantity: 600 mg

Available from:

Sandoz Pty Ltd

Pharmaceutical form:

Tablet, film coated

Composition:

Excipient Ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; sunset yellow FCF aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350

Administration route:

Oral

Units in package:

60s

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Adult patients Darunavir (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adult patients.,Paediatric patients Darunavir (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.

Product summary:

Visual Identification: Orange, oval shaped film coated tablet, debossed with '600' on one side and plain on the other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Registered

Authorization date:

2022-04-22